Reported 9 months ago
Eli Lilly's stock has been on the rise, with its share price up over 50% year to date. Despite trading at a high valuation, there are two reasons why the stock may continue to climb. Firstly, Eli Lilly is struggling to meet the demand for its popular treatments, such as Mounjaro and Zepbound, leading to significant investments in expanding production capacity. Secondly, increased insurance coverage for Zepbound, potentially for treating conditions like sleep apnea, could further boost demand and revenue. These factors suggest that Eli Lilly's stock has the potential for further growth despite its current valuation.
Source: YAHOO